Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Assay Detects Hepatitis B in Multiple Specimens

By LabMedica International staff writers
Posted on 25 Apr 2018
Hepatitis B virus (HBV) infection has led to more than 686,000 deaths worldwide per year. Approximately two billion individuals worldwide are infected with HBV and are at risk of developing cirrhosis and hepatocellular carcinoma, which ranks fifth in terms of malignant cancer mortality.

A novel HBV assay that offers advantages over currently used methods because it has the capability to detect closed circular DNA (cccDNA) in serum, single cells, and preserved tissue samples. This assay can be used to diagnose hepatocellular carcinoma (HCC) at an earlier stage to manage treatment more effectively.

Scientists at the Wuhan University (Wuhan, China) enrolled a total of 168 patients with HBV infection (HBsAg/HBV-DNA positive) in a study between December 2013 and November 2015 at the Zhongnan Hospital. The study included 79 cases of non-HCC patients, 56 without and 23 with cirrhosis; 50 males and 29 females; mean age, 41.7 ±12.8 years, and 89 cases of HCC patients, 75 males and 14 females; mean age, 53.4 ±15.3years. In total, 79 serum samples were collected from non-HCC patients, 68 preoperative serum samples on the first day after hospital admission and 14 paired formalin-fixed paraffin embedded (FFPE) tumor tissues, as well as 21 non-paired FFPE tumor tissues from HCC patients.

Serum HBV-DNA copy number was assayed with COBAS TaqMan 48 kit. The serological HBsAg, hepatitis B s antibody (HBsAb), HBeAg, hepatitis B e antibody (HBeAb), hepatitis B c antibody (HBcAb), and anti-HCV were detected by Architect chemiluminescent enzyme immunoassays. The cccDNA copy number was quantified using the QX200 Droplet Digital PCR system. Clinical biochemical parameters and tumor biomarkers were measured by an automatic chemistry analyzer.

The team found ddPCR was useful to identify which patients might be harboring hepatocellular carcinoma and found that almost 90% of 68 HCC patients were cccDNA-positive compared to 53% of 79 non-HCC patients. Serum cccDNA copy number was found to be higher in HCC patients compared to non-HCC patients. The combined analysis of serum cccDNA and HBV-DNA distinguished HCC patients from non-HCC patients. The investigators were also able to confirm that serum cccDNA was positively correlated with levels of cccDNA measured in liver samples.

Song-Mei Liu, MD, PhD, the lead investigator, said, “The development of HCC is strongly associated with HBV. Recently, several new antiviral strategies targeting cccDNA have been established to improve HBV clearance. It is of great clinical significance to provide an accurate and sensitive approach for cccDNA detection. With this method, more and more patients with chronic HBV will have precision treatment available to prevent or delay HCC occurrence, and HCC in patients could be diagnosed at an earlier stage.” The study was published on April 12, 2018, in The Journal of Molecular Diagnostics.

Related Links:
Wuhan University


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Biological Indicator Vials
BI-O.K.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.